Posted by Michael Wonder on 10 Jun 2020
Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo and Riximyo
9 June 2020 - These two approvals mark an important milestone for Sandoz Canada, bringing its biosimilars into oncology at a time when its biopharmaceutical portfolio already included products in immunology and endocrinology.
Sandoz Canada announced today that Health Canada has approved Ziextenzo (pegfilgrastim, reference biologic drug: Neulasta®) and Riximyo (rituximab, reference biologic drug: Rituxan) for marketing in Canada.
Sandoz Canada received a Notice of Compliance from Health Canada on 21 April 2020, for the use of Ziextenzo to reduce the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy. Riximyo was approved on 28 April 2020, to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis.
